61.22
-0.13%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Alcon
Its shares trade on SIX under the ticker ALC.SW. It has been listed since 9 April 2019. In the fiscal year to 31 December 2025, it reported revenue of $8.86bn and net income of $834.3m. At that date it held total assets of $25.63bn and shareholders' equity of $17.90bn.
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. The company is headquartered in Fribourg, Fribourg. The company went IPO on 2019-04-09. The firm operates mainly as an eye care device company. Alcon AG reports its activities into two segments: Surgical and Vision Care. The surgical segment provides a line of ophthalmic surgical products that enable surgeons to achieve accurate results. Its surgical portfolio includes technologies and devices for cataract, retinal, refractive surgery, as well as advanced technology intraocular lenses (ATIOLs) to treat cataracts and refractive errors, such as presbyopia and astigmatism. The surgical segment also includes advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery. The Vision Care segment manufactures contact lenses and lens care products, such as products for dry eye, contact lens care, ocular allergies, as well as ocular vitamins and redness relievers. The firm also offers continuing education for eye care professionals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 9 Apr 2019
- Employees
- 22,142
- Website
- alcon.com ↗
Leadership
Pay as last reported
- Mr. F. Michael BallNon-Executive Independent Chairman of the Board, since 2016$1.5m
- Mr. David EndicottChief Executive Officer, Director, since 2018$13.2m
- Mr. D. Keith GrossmanIndependent Vice Chairman of the Board, Lead Independent Director$382,381
- Mr. Timothy StonesiferChief Financial Officer
- Mr. Ian BellChief Operating Officer
- Ms. Kimberly MartinSenior Vice President, Chief Human Resource and Corporate Communication Officer
- Mr. Laurent AttiasSenior Vice President - Corporate Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)
- Mr. Leon Duplan FraustroSenior Vice President, President - Americas
- Mr. Rajkumar NarayananSenior Vice President, President - International
- Ms. Lynn BleilIndependent Director$308,470
- Dr. Raquel BonoIndependent Director$276,846
- Dr. Arthur CummingsIndependent Director$300,142
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 90
- Environment
- 88
- Social
- 96
- Governance
- 86
- Direct emissions (scope 1)
- 75,183 t
- Energy emissions (scope 2)
- 236,380 t
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Alcon AG has a strong global presence in the ophthalmic pharmaceuticals and medical devices market.
- The company has a diverse portfolio of innovative products, enabling it to cater to various eye care needs.
- Alcon AG possesses strong research and development capabilities, allowing for the development of cutting-edge technologies and advancements in eye care.
Weaknesses
- Alcon AG faces intense competition from both established players and emerging companies in the ophthalmic industry.
- The company has a high dependence on a few key products, which exposes it to the risk of market fluctuations.
- Alcon AG's profitability may be affected by the need for significant investments in research and development.
Opportunities
- The global demand for eye care products and services is expected to increase due to an aging population and rising prevalence of eye-related disorders.
- Alcon AG can explore expanding its presence in emerging markets, where the demand for eye care products is growing rapidly.
- The company can leverage technological advancements to develop innovative products and gain a competitive edge.
Threats
- Changing regulations and government policies in the healthcare industry pose a threat to Alcon AG's operations and profitability.
- The company may face challenges in effectively managing and protecting its intellectual property rights.
- Alcon AG is exposed to the risk of product recalls, which can significantly damage its reputation and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.